tetano
Editor, Senior Moderator
BMC Neurol
. 2023 Sep 27;23(1):340.
doi: 10.1186/s12883-023-03393-2. Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?
Gautier Breville[SUP] 1 2 [/SUP], François Herrmann[SUP] 3 [/SUP], Dan Adler[SUP] 4 [/SUP], Christine Deffert[SUP] 5 6 [/SUP], Giulia Bommarito[SUP] 7 [/SUP], Patrick Stancu[SUP] 8 [/SUP], Alice Accorroni[SUP] 8 [/SUP], Marjolaine Uginet[SUP] 8 [/SUP], Frederic Assal[SUP] 8 [/SUP], Renaud Tamisier[SUP] 9 [/SUP], Patrice H Lalive[SUP] 8 10 11 [/SUP], Jean-Louis Pepin[SUP] 4 9 [/SUP], Karl-Olof Lövblad[SUP] 12 [/SUP], Gilles Allali[SUP] 8 7 13 [/SUP]
Affiliations
Background: This study evaluates the impact of high risk of obstructive sleep apnea (OSA) on coronavirus disease 2019 (COVID-19) acute encephalopathy (AE).
Methods: Between 3/1/2020 and 11/1/2021, 97 consecutive patients were evaluated at the Geneva University Hospitals with a neurological diagnosis of COVID-19 AE. They were divided in two groups depending on the presence or absence of high risk for OSA based on the modified NOSAS score (mNOSAS, respectively ≥ 8 and < 8). We compared patients' characteristics (clinical, biological, brain MRI, EEG, pulmonary CT). The severity of COVID-19 AE relied on the RASS and CAM scores.
Results: Most COVID-19 AE patients presented with a high mNOSAS, suggesting high risk of OSA (> 80%). Patients with a high mNOSAS had a more severe form of COVID-19 AE (84.8% versus 27.8%), longer mean duration of COVID-19 AE (27.9 versus 16.9 days), higher mRS at discharge (≥ 3 in 58.2% versus 16.7%), and increased prevalence of brain vessels enhancement (98.1% versus 20.0%). High risk of OSA was associated with a 14 fold increased risk of developing a severe COVID-19 AE (OR = 14.52).
Discussion: These observations suggest an association between high risk of OSA and COVID-19 AE severity. High risk of OSA could be a predisposing factor leading to severe COVID-19 AE and consecutive long-term sequalae.
Keywords: COVID-19 encephalopathy; Obstructive sleep apnea; SARS-CoV-2.
. 2023 Sep 27;23(1):340.
doi: 10.1186/s12883-023-03393-2. Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?
Gautier Breville[SUP] 1 2 [/SUP], François Herrmann[SUP] 3 [/SUP], Dan Adler[SUP] 4 [/SUP], Christine Deffert[SUP] 5 6 [/SUP], Giulia Bommarito[SUP] 7 [/SUP], Patrick Stancu[SUP] 8 [/SUP], Alice Accorroni[SUP] 8 [/SUP], Marjolaine Uginet[SUP] 8 [/SUP], Frederic Assal[SUP] 8 [/SUP], Renaud Tamisier[SUP] 9 [/SUP], Patrice H Lalive[SUP] 8 10 11 [/SUP], Jean-Louis Pepin[SUP] 4 9 [/SUP], Karl-Olof Lövblad[SUP] 12 [/SUP], Gilles Allali[SUP] 8 7 13 [/SUP]
Affiliations
- PMID: 37752429
- DOI: 10.1186/s12883-023-03393-2
Background: This study evaluates the impact of high risk of obstructive sleep apnea (OSA) on coronavirus disease 2019 (COVID-19) acute encephalopathy (AE).
Methods: Between 3/1/2020 and 11/1/2021, 97 consecutive patients were evaluated at the Geneva University Hospitals with a neurological diagnosis of COVID-19 AE. They were divided in two groups depending on the presence or absence of high risk for OSA based on the modified NOSAS score (mNOSAS, respectively ≥ 8 and < 8). We compared patients' characteristics (clinical, biological, brain MRI, EEG, pulmonary CT). The severity of COVID-19 AE relied on the RASS and CAM scores.
Results: Most COVID-19 AE patients presented with a high mNOSAS, suggesting high risk of OSA (> 80%). Patients with a high mNOSAS had a more severe form of COVID-19 AE (84.8% versus 27.8%), longer mean duration of COVID-19 AE (27.9 versus 16.9 days), higher mRS at discharge (≥ 3 in 58.2% versus 16.7%), and increased prevalence of brain vessels enhancement (98.1% versus 20.0%). High risk of OSA was associated with a 14 fold increased risk of developing a severe COVID-19 AE (OR = 14.52).
Discussion: These observations suggest an association between high risk of OSA and COVID-19 AE severity. High risk of OSA could be a predisposing factor leading to severe COVID-19 AE and consecutive long-term sequalae.
Keywords: COVID-19 encephalopathy; Obstructive sleep apnea; SARS-CoV-2.